SOX2 antagonizes WWC1 to drive YAP1 activation in esophageal squamous cell carcinoma

Yuhang Chai1 | Qihang Li1 | Hongying Zhao2 | Zhiyu Zhang1,2 | Xiaodan Yu1,3 | Lijuan Pang1 | Zheng Liu2 | Jin Zhao1 | Lianghai Wang1 | Feng Li1,2

1Department of Pathology and Key Laboratory of Xinjiang Endemic and Ethnic Diseases/the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, China
2Department of Pathology and Medical Research Center, Beijing Chaoyang Hospital, Capital Medical University, Beijing, China
3Department of Stomatology, The First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, China

Correspondence
Lianghai Wang and Feng Li, Department of Pathology and Key Laboratory of Xinjiang Endemic and Ethnic Diseases/the First Affiliated Hospital, Shihezi University School of Medicine, Shihezi, Xinjiang, China.
Email: lh_wang@shzu.edu.cn; lifeng7855@126.com

Abstract
Whether SOX2 and ACTL6A/TP63 interact with the Hippo-YAP1 pathway in esophageal squamous cell carcinoma (ESCC) remains unclear. Here, we reveal that SOX2, ACTL6A, and TP63 are co-amplified and upregulated in ESCC samples. Multiple SOX2 binding peaks in the locus of WWC1, a Hippo-YAP1 regulator, and an inverse correlation between the expression of SOX2 and WWC1 are identified, suggesting direct repression of WWC1 by SOX2. Expression scores of SOX2 are higher in tumors than normal tissues and positively correlated with nuclear YAP1 staining in primary ESCC. Moreover, SOX2 gain-of-function significantly promotes nuclear YAPI expression in ESCC cells while silencing of SOX2 expression inhibits YAP1 activation. SOX2 overexpression leads to a significant enhancement of cell migration and invasion as well as chemoresistance to cisplatin, whereas knockdown of SOX2 or ectopic expression of WWC1 suppresses the SOX2-induced migration ability and invasive potential. Disruption of this SOX2-WWC1-YAP1 axis could be a therapeutic strategy for SOX2-dependent tumors.

KEYWORDS
ESCC, SOX2, WWC1, YAP1
INTRODUCTION

Esophageal cancer is one of the most common gastrointestinal malignancies in the world. According to GLOBOCAN 2018, this disease ranks as the seventh most frequently diagnosed cancer (572,000 new cases) and the sixth leading cause of cancer death (509,000 deaths), with an estimated 1 in every 20 cancer deaths due to esophageal cancer. The two major histological types of esophageal cancer are esophageal squamous cell carcinoma (ESCC) and esophageal adenocarcinoma. ESCC accounts for 90% of patients with esophageal cancer worldwide, especially in the East, East Africa, and South America. The 5-year survival rate of all patients with esophageal cancer is less than 20% even in developed countries. The occurrence of esophageal cancer is a multi-factor, including environmental factors (such as smoking and drinking) and genetic variants (such as chromosomal changes and methylation), and multi-step process. However, the detailed molecular mechanisms in ESCC development and progression remain to be fully elucidated.

SOX (SRY-related HMG box) is a family of SRY (sex determination region of y chromosome) related genes, encoding a series of transcription factors involved in embryonic development and cellular regulation. SOX2 is a member of the SOX family B1 group and is located on chromosome 3q26.3–q27.8 Abnormal expression of SOX2 may be associated with human squamous cell carcinomas of the lung and esophagus (caused by amplification of the SOX2 locus), and human osteosarcoma, and melanoma. Moreover, the TP63 locus is frequently co-amplified with SOX2, given that TP63 is located approximately 7 Mb from the SOX2 locus. SOX2 and p63 may be co-localized on the genome in SCC and collaboratively regulate gene expression in squamous cell carcinoma. ACTL6A, which is located approximately 10 Mb apart on chromosome 3q, is frequently co-amplified and co-expressed with TP63 in a substantial proportion of head and neck squamous cell carcinomas (HNSCC).

The Hippo signaling pathway is a potent regulator of cell proliferation, differentiation, and tissue homeostasis. The core components of the Hippo kinase/transcription modules are evolutionarily conserved. Yes-associated protein 1 (YAP1) and its paralog transcriptional co-activator with PDZ-binding motif (TAZ; also known as WWTR1) are two major downstream effectors of the Hippo kinase cascade. YAP1/TAZ function as transcriptional co-activators that induce transcription of downstream cell-proliferative and anti-apoptotic genes via interactions with transcription factors, primarily TEA domain family members (TEAD) in the nucleus. Activation of the Hippo kinase cascade by various stimuli phosphorylate and inactivate YAP1 by triggering either the cytoplasmic retention or the degradation of YAP1, ultimately preventing the transcriptional output module. Kidney and brain expressed protein (KIBRA; also known as WWC1) acts as an upstream tumor suppressor that form a complex with neurofibromatosis 2 (NF2; also known as Merlin) to activate the Hippo kinase cassette and prevent YAP1 and TAZ activation.

It has been reported that the Hippo pathway effector YAP1 is a direct transcriptional target of SOX2 in mesenchymal stem cells and osteoprogenitors. WW1C and NF2, two Hippo activators, appear to be directly repressed at the transcriptional level by SOX2 in human osteosarcomas. Moreover, ACTL6A and p63 could physically interact, cooperatively suppressing WW1C transcription to activate the Hippo-YAP1 pathway and thus promoting tumorigenesis in HNSCC. However, whether and how SOX2, ACTL6A, or TP63 interacts with the Hippo-YAP1 pathway in ESCC remain to be determined.

Herein, we sought to identify the genetic alterations and expression profiles of related genes in ESCC. We have also used in vitro gain-of-function model to assess the regulation mechanism.

MATERIALS AND METHODS

Human tissue samples

A total of 101 ESCC and 40 non-cancerous adjacent tissue samples were obtained from the First Affiliated Hospital of Shihezi University School of Medicine, Xinjiang Yili Prefecture Friendship Hospital, and the People’s Hospital of Xinjiang Uyghur Autonomous Region in the years 2004-2013. Informed consents were obtained from the patients, and the study was approved by the Ethics Committee of the First Affiliated Hospital, Shihezi University School of Medicine.

Immunohistochemistry

Immunohistochemical stainings of SOX2 and YAP1 were performed using primary antibodies against SOX2 (#2748, Cell Signaling Technology) and YAP1 (#14074, Cell Signaling Technology) on a BOND-MAX Automated IHC/ISH Stainer (Leica) according to previously established protocols. Following staining, tissue microarray sections were dehydrated in graded alcohol, cleared in xylene, and mounted.

Immunostaining degree of each sample was scored as previously described by pathologists based on nuclear staining intensity (intensity score) and percentage of positive cells (extent score). The final immunoreactivity score for each case is the product of the intensity score and the extent score.

Cell culture

ESCC cell lines including Eca109, EC9706, TE-1, and KYSE150 were purchased from the Cell Bank of Type Culture Collection of Chinese Academy of Sciences. All cells were
maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum at 37°C in a humidified incubator under 5% CO₂ atmosphere. Eca109 cells stably expressing SOX2 (Eca109-SOX2) were developed by transducing parental cells with SOX2 lentiviruses and selecting with 5 μg/mL Puromycin.

2.4 Western blotting

Total protein or nuclear and cytoplasmic fractions were isolated from cultured cells using RIPA buffer (#R0010) or a Nuclear and Cytoplasmic Protein Extraction Kit (#P0027, Beyotime Biotechnology) supplemented with protease inhibitors following the manufacturers’ instructions, respectively. Equal amounts of lysates were electrophoretically resolved and transferred to PVDF membranes. After blocking with 5% skimmed milk, the membranes were incubated with primary antibodies against SOX 2 (#2748, 1:500; Cell Signaling Technology), YAP1 (#14074, 1:1000; Cell Signaling Technology), TAZ (#4883, 1:1000; Cell Signaling Technology), β-actin (1E9A3, 1:1000; ZSGB-BIO), α-tubulin (AF0001, Beyotime Biotechnology), Lamin B1 (AF1408, Beyotime Biotechnology), and appropriate peroxidase-conjugated secondary antibodies. The signals were detected using enhanced chemiluminescence (Millipore).

2.5 Immunofluorescence

Cells cultured on glass coverslips were fixed with 4% paraformaldehyde followed by permeabilization with 0.1% Triton X-100. Subsequently, cells were blocked with 1% BSA and incubated with YAP1 antibody, washed with PBS, incubated with Alexa Fluor 594-Conjugated Goat anti-Rabbit IgG (H + L) (#ZF-0516, ZSGB-BIO) as the secondary antibody, and counterstained with DAPI (#C1002, Beyotime Biotechnology). Images were taken at 60X magnification.

2.6 Transwell assay

Migration and invasion assays were carried out using Transwell chambers (Corning) according to our previous work.25 Migratory or invasive cells on the lower membrane surface were fixed, stained with 1% crystal violet and counted under a light microscope in five random fields.

FIGURE 1 SOX2 is amplified and upregulated together with ACTL6A and TP63 in ESCC. (A) Gene copy-number and mutation data from the TCGA for ESCC, showing frequent co-amplification of SOX2, ACTL6A, and TP63. (B–D) SOX2, ACTL6A, and TP63 mRNA expression correlate with their gene copy number, respectively. Data obtained from RNAseqV2 and GISTIC, respectively, of the TCGA ESCC (n = 96)
**FIGURE 2** SOX2 is a direct transcriptional suppressor of the Hippo regulator WWC1. (A–B) Trace from SOX2 (A) and p63 (B) ChIP-seq data in ESCC cell line TT showing binding peaks around the indicated genes. (C) Correlation between SOX2 and WWC1, YAP1, and NF2 in SCC samples from the TCGA Esophageal Cancer (ESCA). (D) Correlation between ACTL6A, TP63, and WWC1 in SCC samples from ESCA dataset.
2.7 Cell viability

Cell viability in the presence of increasing concentrations of cisplatin was measured using the Cell Counting Kit-8 (CCK-8) as previously described. Absorbance at 450 nm was measured with a microplate reader (BIO-RAD xMark).

2.8 Xenograft assay

Five-week-old female BALB/C nude mice (Beijing Vital River Laboratory Animal Technology) were used in this study. One million KYSE150 cells grown at logarithm phase were subcutaneously injected into the armpit of mice to establish ESCC xenografts. Tumor volume was measured with a caliper and calculated using the formula length × width² × π/6. The mice were sacrificed at the end of the experiments, and the tumors were excised and weighed. All procedures were performed with approval from the Animal Experimental Ethical Inspection of First Affiliated Hospital, Shihezi University School of Medicine.

2.9 Statistical analysis

Statistical analyses were performed using GraphPad Prism 7 or IBM SPSS Statistics. Pearson and Spearman's correlations were used to evaluate the significance of the association.
Comparison between groups was conducted using a Mann-Whitney U-test or two-tailed Student’s t-test. Numerical data were presented as means ± SEM unless stressed. A P value of <.05 was considered significant.

3 | RESULT

3.1 | SOX2, ACTL6A, and TP63 are co-amplified and upregulated in ESCC

It has been previously suggested that SOX2 and ACTL6A/TP63 can control the activation of the Hippo-YAP1 pathway. As a first step toward uncovering the functional contribution of SOX2, ACTL6A, and TP63 to Hippo-YAP1 pathway in ESCC, we analyzed the genetic alterations of ESCC patients from the Cancer Genome Atlas Network (TCGA). A substantial proportion of the samples (34 cases; 35.4%) exhibit co-amplification of the SOX2, ACTL6A, and TP63 loci, while WWC1, NF2, and YAP1, components of the Hippo-YAP1 signaling, were barely mutated among these patients (Figure 1A). Moreover, expression of SOX2, ACTL6A, and TP63 correlated with their copy number status across ESCC tumors in the TCGA dataset, respectively (Figure 1B–D).

3.2 | SOX2 mediates direct repression of the Hippo-YAP1 regulator WWC1 in ESCC

To understand the transcriptional regulation involved in the YAP1 activation in ESCC, we first assessed chromatin immunoprecipitation/high-throughput sequencing (ChIP-seq) data of endogenous SOX2 and p63 in ESCC cell line TT, then integrated with RNA-seq data from human ESCC in the TCGA dataset (Figure 2). Intriguingly, ChIP-seq data for SOX2 binding showed multiple SOX2 binding peaks in the loci of WWC1, NF2, and YAP1 (Figure 2A). However, among these candidate transcription targets, significant inverse correlation with SOX2 expression was only identified for WWC1 (Pearson $r = -.255, P = .0125$; Spearman
CHAI et al.

$r = -.338, P = .0008$), but not for $NF2$ and $YAP1 (P > .05; Figure 2C). Although a reverse trend between $ACTL6A/TP63$ and $WWC1$ was observed in the in vivo context (Figure 2D), there was no binding site of p63 to the $WWC1$ locus (Figure 2B). Together, these findings suggest $WWC1$ locus being a direct target of SOX2.
3.3 | SOX2 is overexpressed and controls YAP1 activity in ESCC

To provide further evidence for the control of Hippo-YAP1 signaling pathway mediated by SOX2 in human ESCC, we characterized SOX2 and YAP1 expression by immunohistochemistry staining in a tissue microarray derived from an ESCC cohort of 101 patients. Results showed that SOX2 protein was mainly located in the nucleus of ESCC cells and the expression scores of SOX2 in ESCC were significantly higher than that in adjacent normal tissues (Figure 3A). Among them, 40 cases (40/101, 39.6%) of ESCC showed high expression score (>median) of SOX2 protein, whereas only 5 cases (5/40, 12.5%) of normal tissues exhibited high SOX2 expression. Stronger immunosignal in the nucleus of tumor cells was also observed for YAP1. Importantly, we found increased nuclear YAP1 staining in primary ESCC specimens with high levels of SOX2 (Figure 3B). Quantification of this series of samples showed that nuclear YAP1 expression was higher in ESCC with high SOX2 scores than that with low expression of SOX2 (Figure 3C). Furthermore, nuclear YAP1 expression score was positively associated with elevated SOX2 (Pearson r = .313, P = .0025; Spearman r = .233, P = .0262; Figure 3D).

Next, we sought to determine whether SOX2 gain-of-function was associated with YAP1 regulation in ESCC cells. Among a panel of ESCC cell lines, the expression of endogenous SOX2 protein was low in Eca109 and EC9706 cells (Figure 4A). Eca109 cells inoculated with SOX2-over-expressing lentivirus (Eca109-SOX2) showed higher expression of SOX2 protein than cells treated with a lentiviral vector (Eca109-vector) as expected. The expression of total YAP1 protein increased after overexpression of SOX2 in Eca109 cells as detected by Western blotting (Figure 4B). Remarkably, immunofluorescence assay for YAP1 showed that the percentage of Eca109 cells staining nuclear YAP1 was significantly increased following overexpression of SOX2 (Figure 4C). We also analyzed YAP1 localization by immunoblot analysis of fractionated lysates from ESCC cells. SOX2 overexpression led to increased nuclear YAP1 level in Eca109-SOX2 cells, while YAP1 was mainly in the cytoplasm in parental cells (Figure 4D). Conversely, knockdown of SOX2 expression by shRNAs in KYSE150 cells inhibited the nuclear levels of YAP1, but not TAZ (Figure 4E,F), confirming the control of YAP1 localization by SOX2.

3.4 | SOX2 overexpression promotes aggressive phenotypes that can be antagonized by WWC1

YAP1 is pervasively activated in human cancers including ESCC, where its activation is required to instruct malignant properties, such as chemoresistance and metastasis. To determine the effect of SOX2 on the motility of ESCC cells, Transwell assays were performed. Results showed that overexpression of SOX2 in Eca109 cells resulted in a significant enhancement of their migration ability and invasive potential compared to control groups (Figure 5A,B). Furthermore, we found that enhanced SOX2 expression in Eca109 cells promoted chemoresistance to cisplatin, one of the most frequently used chemotherapeutic drug for esophageal cancer, as demonstrated by a shift in the IC50 (Figure 5C). On the contrary, silencing of SOX2 by shRNA markedly reduced migration and invasion of KYSE150 cells (Figure 5D,E). We next established a xenograft model in nude mice to address the role of SOX2 in tumor growth. Knockdown of SOX2 potently suppressed KYSE150-derived xenograft growth, as measured by tumor volume and tumor weight (Figure 5F,G). To test the potential contribution of WWC1 in ESCC, we also performed gain-of-function experiments. Overexpression of the repressed WWC1 by a plasmid in Eca109-SOX2 cells potently abrogated the SOX2-induced migration and invasion (Figure 5H,I), providing evidence that repression of WWC1 is required for the functionality of SOX2 in ESCC.

4 | DISCUSSION

Recent evidence suggests that SOX2 and ACTL6A/p63 may regulate Hippo pathway components in osteosarcoma and HNSCC, respectively. In this report, we show that SOX2, ACTL6A, and TP63 are co-amplified and upregulated in ESCC samples. Through integrating genomic analysis and transcriptome profiling of these transcription factors, we outline a pathway in which SOX2-mediated direct repression of the Hippo regulator WWC1 in ESCC. SOX2-promoted YAP1 activation is confirmed both in clinical samples and ESCC cells. Of note, while SOX2 is supposed to bind the 3′ untranslated portion of WWC1 mRNA in osteosarcoma, multiple SOX2 binding peaks are identified in the upper region of WWC1 in ESCC TT cells, suggesting SOX2 can regulate the Hippo-YAP1 signaling in a context-dependent manner. It is noteworthy that regulation of TAZ by SOX2 is distinct from that of YAP1 in ESCC cells, although YAP1 and TAZ are often described to be equivalent downstream of the Hippo pathway. Consistent with this finding, TAZ expression is not decreased in SOX2-depleted osteoprogenitors. Furthermore, YAP1 shows different functional roles compared to TAZ in osteosarcoma and hepatocellular carcinoma. SOX2 has been implicated in tumorigenicity, drug resistance, and metastasis in at least 25 human cancers. Regarding clinical prognosis for cancer patients, high SOX2 expression has been linked to poor prognosis and increased metastatic capacity in the majority of cancers, such as ESCC and breast cancer. However, a few
studies on the role of SOX2 in cancer development have led to contrasting findings: low or negative SOX2 expression is associated with worse prognosis in at least four cancers,29 including gastric cancer,34,35 squamous cell lung cancer,36 and ESCC.37,38 Given the conflicting reports regarding SOX2 expression and patient prognosis, there are clear needs for further investigation into the clinical implications of SOX2, particularly how SOX2 influences tumor progression. SOX2 has been described to promote tumor aggressiveness and to promote metastasis by activating the STAT3/HIF-1α pathway.40 Targeted silencing of SOX2 by an artificial transcription factor shows an anti-tumor effect in ESCC.41 In the present study, ectopic SOX2 expression promotes migration, invasion, and drug resistance of ESCC cells, while knockdown of SOX2 or WWC1 overexpression promotes migration, invasion, and drug resistance of ESCC cells, while knockdown of SOX2 or WWC1 overexpression diminishes their migration ability and invasive potential.

In summary, SOX2 is highly expressed in ESCC and activates YAP1 signaling by direct suppressing WWC1 transcription, thus promoting the migration, invasion, and drug resistance. This SOX2-WWC1-YAP1 axis in ESCC may serve as a target for cancer therapy.

ACKNOWLEDGMENTS
This work was supported by the National Natural Science Foundation of China (Nos. 81902850, 81602810, 81560399, 81460416), the Ministry of Science and Technology of China (2012AA02A503), the State Scholarship Foundation of China (201608650002), the Youth Science and Technology Innovation Leading Talents Project of Corps (2017CB004), and the Xinjiang Production and Construction Corps Key Areas Innovation Team Project (2018CB002).

CONFLICTS OF INTEREST
The authors declare no conflict of interest.

DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Lianghai Wang https://orcid.org/0000-0003-3128-7780

REFERENCES
1. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
2. Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer. Nat Rev Dis Primers. 2017;3:17048.
3. Wang Q-L, Xie S-H, Li W-T, et al. Smoking cessation and risk of esophageal cancer by histological type: systematic review and meta-analysis. J Natl Cancer Inst. 2017;109(12).
4. Cui RI, Katamani Y, Takahashi A, et al. Functional variants in ADH1B and ALDH2 coupled with alcohol and smoking synergistically enhance esophageal cancer risk. Gastroenterology. 2009;137:1768-1775.
5. Dong Y, Yi X, Yujie Z, Huixia Z, Yan C. Relationship between the methylation of folic acid metabolism-related genes and the incidence and prognosis of esophageal cancer among Ethnic Kazakhs. J Cancer. 2018;9:2865-2875.
6. Wang L, Zhang Z, Yu X, et al. Unbalanced YAP-SOX9 circuit drives stemness and malignant progression in esophageal squamous cell carcinoma. Oncogene. 2018;38(12):2042-2055.
7. Kaur G, Delluc-Clavieres A, Poon IK, Forwood JK, Glover DJ, Jans DA. Calmodulin-dependent nuclear import of HMG-box family nuclear factors: importance of the role of SRY in sex reversal. Biochem J. 2010;430:39-48.
8. Hussenet T, Dali S, Exinger J, et al. SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas. PLoS ONE. 2010;5:e8960.
9. Bass AJ, Watanabe H, Mermel CH, et al. SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet. 2009;41:1238-1242.
10. Rudin CM, Durinck S, Stawiski EW, et al. Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer. Nat Genet. 2012;44:1111-1116.
11. Basu-Roy U, Seo E, Ramanathapuram L, et al. Sox2 maintains self renewal of tumor-initiating cells in osteosarcomas. Oncogene. 2012;31:2270-2282.
12. Laga AC, Lai C-Y, Zhan Q, et al. Expression of the embryonic stem cell transcription factor SOX2 in human skin: relevance to melanocyte and melker cell biology. Am J Pathol. 2010;176:903-913.
13. Watanabe H, Ma Q, Peng S, et al. SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. J Clin Invest. 2014;124:1636-1645.
14. Saladi SV, Ross K, Karaavaz M, et al. ACTL6A is co-amplified with p63 in squamous cell carcinoma to drive YAP activation, regenerative proliferation, and poor prognosis. Cancer Cell. 2017;31:35-49.
15. Hansen CG, Moroiishi T, Guan KL. YAP and TAZ: a nexus for Hippo signaling and beyond. Trends Cell Biol. 2015;25:499-513.
16. Dong J, Feldmann G, Huang J, et al. Elucidation of a universal size-control mechanism in Drosophila and mammals. Cell. 2007;130:1120-1133.
17. Zhao B, Wei X, Li W, et al. Inactivation of YAP oncoprotein by the Hippo pathway is involved in cell contact inhibition and tissue growth control. Genes Dev. 2007;21:2747-2761.
18. Moroiishi T, Hansen CG, Guan KL. The emerging roles of YAP and TAZ in cancer. Nat Rev Cancer. 2015;15:73-79.
19. Baumgartner R, Poernbacher I, Buser N, Hafen E, Stocker H. The WW domain protein Kiaa acts upstream of Hippo in Drosophila. Dev Cell. 2010;18:309-316.
20. Yu J, Zheng Y, Dong J, Klusza S, Deng WM, Pan D. Kiaa functions as a tumor suppressor protein that regulates Hippo signaling in conjunction with Merlin and Expanded. Dev Cell. 2010;18:288-299.
21. Genevet A, Wehr MC, Brain R, Thompson BJ, Tapon N. Kiaa is a regulator of the Salvador/Warts/Hippo signaling network. Dev Cell. 2010;18:300-308.
22. Seo E, Basu-Roy U, Gunaratne P, et al. SOX2 regulates YAP1 to maintain stemness and determine cell fate in the osteo-adipo lineage. Cell Rep. 2013;3:2075-2087.
23. Basu-Roy U, Bayin NS, Rattanakorn K, et al. Sox2 antagonizes the Hippo pathway to maintain stemness in cancer cells. Nat Commun. 2015;6:6411.
24. Wang L, Li J, Hou J, et al. p53 expression but not p16(INK4A) correlates with human papillomavirus-associated esophageal squamous cell carcinoma in Kazakh population. Infect Agents Cancer. 2016;11:19.
25. Wang L, Yu X, Zhang Z, et al. Linc-ROR promotes esophageal squamous cell carcinoma progression through the derepression of SOX9. J Exp Clin Cancer Res. 2017;36:182.
26. Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the roots of cancer. Cancer Cell. 2016;29:783-803.
27. Moleirinho S, Chang N, Sims AH, et al. KIBRA exhibits MST-independent functional regulation of the Hippo signaling pathway in mammals. Oncogene. 2013;32:1821-1830.
28. Hayashi H, Higashi T, Yokoyama N, et al. An imbalance in TAZ and YAP expression in hepatocellular carcinoma confers cancer stem cell-like behaviors contributing to disease progression. Can Res. 2015;75:4985-4997.
29. Wuebben EL, Rizzino A. The dark side of SOX2: cancer—a comprehensive overview. Oncotarget. 2017;8:44917-44943.
30. Saigusa S, Mohri Y, Ohl M, et al. Podoplanin and SOX2 expression in esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy. Oncol Rep. 2011;26:1069-1074.
31. Wang Q, He W, Lu C, et al. Oct3/4 and Sox2 are significantly associated with an unfavorable clinical outcome in human esophageal squamous cell carcinoma. Anticancer Res. 2009;29:1233-1241.
32. Lengerke C, Fehm T, Kurth R, et al. Expression of the embryonic stem cell marker SOX2 in early-stage breast carcinoma. BMC Cancer. 2011;11:42.
33. Liu P, Tang H, Song C, et al. SOX2 promotes cell proliferation and metastasis in triple negative breast cancer. Front Pharmacol. 2018;9:942.
34. Zhang X, Yu H, Yang Y, et al. SOX2 in gastric carcinoma, but not Hath1, is related to patients’ clinicopathological features and prognosis. J Gastrointest Surg. 2010;14:1220-1226.
35. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y. SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer. 2008;98:824-831.
36. Wilbertz T, Wagner P, Petersen K, et al. SOX2 gene amplification and protein overexpression are associated with better outcome in squamous cell lung cancer. Modern Pathol. 2011;24(7):944-953.
37. Maehara R, Fujikura K, Takeuchi K, et al. SOX2-silenced squamous cell carcinoma: a highly malignant form of esophageal cancer with SOX2 promoter hypermethylation. Mod Pathol. 2018;31(1):83-92.
38. Wang H, Zhou Y, Liu Q, Xu J, Ma Y. Prognostic value of SOX2, Cyclin D1, P53, and ki-67 in patients with esophageal squamous cell carcinoma. Oncotarget. 2018;11:5171-5181.
39. Gen Y, Yasui K, Nishikawa T, Yoshikawa T. SOX2 promotes tumor growth of esophageal squamous cell carcinoma through the AKT/mammalian target of rapamycin complex 1 signaling pathway. Cancer Sci. 2013;104:810-816.
40. Gao H, Teng C, Huang W, Peng J, Wang C. SOX2 promotes the epithelial to mesenchymal transition of esophageal squamous cells by modulating slug expression through the activation of STAT3/HIF-alpha signaling. Int J Mol Sci. 2015;16:21643-21657.
41. Yokota E, Yamatsuji T, Takaoka M, et al. Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma. Oncotarget. 2017;8:103063-103076.

How to cite this article: Chai Y, Li Q, Zhao H, et al. SOX2 antagonizes WWC1 to drive YAP1 activation in esophageal squamous cell carcinoma. Cancer Med. 2019;8:7055–7064. https://doi.org/10.1002/cam4.2569